GlassScriptPhysician profile
Brooke W Jones
NPI 1912977059
$259,023.23
in general payments reported to CMS, 2019-2025
40 companies · $97K in 2025
The $97K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $25K · 2022: $29K · 2023: $45K · 2024: $64K · 2025: $97K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $138K · Travel and Lodging: $31K · Food and Beverage: $20K · Consulting Fee: $15K · Education: $531.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $138,372.50 |
| Travel and Lodging | $31,452.71 |
| Food and Beverage | $20,147.07 |
| Consulting Fee | $15,242.75 |
| Education | $531.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $89,748.13 | 2021-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $52,862.12 | 2021-2025 | |
| Janssen Biotech, INC. | $49,776.66 | 2021-2025 | Tremfya, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $24,991.45 | 2021-2025 | Ilumya, Blu-U, Absorica Ld |
| Lilly USA, LLC | $21,866.11 | 2021-2025 | Olumiant, Taltz, Ebglyss |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $3,337.30 | 2021-2025 | Cabtreo, Siliq, Targretin |
| Leo Pharma INC. | $3,042.33 | 2021-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $2,499.84 | 2022-2025 | Sotyktu, Sprycel |
| Regeneron Healthcare Solutions, INC. | $2,480.41 | 2021-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $2,247.17 | 2021-2025 | |
| Genzyme Corporation | $1,817.38 | 2021-2025 | |
| Pfizer INC. | $601.08 | 2021-2025 | |
| Merz North America, INC. | $457.56 | 2022-2025 | |
| Incyte Corporation | $373.73 | 2021-2025 | Opzelura |
| Amgen INC. | $369.66 | 2022-2025 | Otezla, Otezla |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $347.49 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $290.18 | 2021-2025 | Nemluvio, Dysport, Aklief |
| Genentech USA, INC. | $209.75 | 2021-2025 | Xolair, Erivedge |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.87 | 2023-2025 | Spevigo |
| Vyne Pharmaceuticals INC. | $148.79 | 2021 | |
| Sanofi-Aventis U.S. LLC | $130.98 | 2021 | |
| Janssen Scientific Affairs, LLC | $128.99 | 2022-2024 | Tremfya |
| Arcutis Biotherapeutics, INC. | $123.56 | 2023-2024 | Zoryve |
| Almirall LLC | $115.84 | 2021-2023 | Seysara |
| Organon LLC | $111.43 | 2025 | |
| Sanofi Pasteur INC. | $106.42 | 2023-2024 | |
| Epi Health, LLC | $91.42 | 2021-2022 | |
| Verrica Pharmaceuticals INC. | $90.75 | 2023-2024 | Ycanth |
| Biofrontera INC. | $83.32 | 2021-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Novo Nordisk INC | $73.82 | 2022-2023 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $52.46 | 2024 | Airsupra |
| Neurocrine Biosciences, INC. | $51.91 | 2024 | Ingrezza |
| Mayne Pharma Commercial LLC | $48.80 | 2021-2023 | |
| Kyowa Kirin, INC. | $43.41 | 2021-2022 | |
| Organogenesis INC. | $35.59 | 2022 | |
| Journey Medical Corporation | $32.32 | 2022-2023 | |
| Helsinn Therapeutics (U.S.), INC. | $27.06 | 2021 | |
| Allergan, INC. | $19.55 | 2022 | |
| Optinose US, INC. | $15.74 | 2022 | |
| Sebela Pharmaceuticals INC. | $14.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.